托弗森:与SOD1突变相关的肌缩侧面硬化症的综述
Aisling McGuigan1, Hannah A Blair2
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.
CNS drugs
|July 10, 2025
概括
托弗森是首个批准用于与SOD1突变相关的肌缩侧面硬化症 (ALS) 的治疗方法. 它有效降低神经退行症的生物标志物,显示出在ALS患者中减缓疾病进展的潜力.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 药理学 药理学 是一个学科.
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种进展性神经退行性疾病.
- 超氧化解突变酶1 (SOD1) 基因的突变是ALS的罕见原因.
- 目前的ALS治疗方法有限,这凸显了对疾病修饰疗法的需求.
研究的目的:
- 评估托弗森在SOD1突变ALS患者的疗效和安全性.
- 评估托弗森对神经轴损伤生物标志物和SOD1蛋白水平的影响.
- 调查托弗森对ALS的功能结果的长期影响.
主要方法:
- 第三阶段,多国,随机,安慰剂控制的VALOR试验.
- 托弗森的内注射 托弗森的内注射
- 测量血神经丝光链和脑脊液SOD1蛋白水平.
- 使用ALS评级表来评估功能结果.
主要成果:
- 托弗森显著降低了血神经丝和CSF SOD1蛋白水平.
- 在开放式扩展期间,生物标志物的减少持续.
- 在最初的28周试验中,托弗森和安慰剂之间的功能衰退没有显著差异.
- 在延伸研究中,早期开始使用托弗森与功能衰退的减缓有关.
结论:
- 托弗森是首个批准用于SOD1-ALS的疾病修饰疗法.
- 它表现出有利的利益与风险的概况.
- 托弗森可降低SOD1突变的ALS患者神经退行的主要生物标志物.
更多相关视频
06:49A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
Published on: October 6, 2015
19.9K
11:12Assay Development for High Content Quantification of Sod1 Mutant Protein Aggregate Formation in Living Cells
Published on: October 4, 2017
7.3K
相关概念视频
Parkinson's Disease: Treatment
389
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
389
Parkinson's Disease: Overview
716
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
716
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Alzheimer's Disease: Overview
675
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
675
Amyloid Fibrils
9.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.9K
Satellite Stem Cells and Muscular Dystrophy
2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K
